Is Cidara Therapeutics, Inc. overvalued or undervalued?

Jun 25 2025 09:08 AM IST
share
Share Via
As of October 5, 2023, Cidara Therapeutics, Inc. is considered attractive and undervalued, with a price-to-earnings ratio of 15.2 and a price-to-book ratio of 1.8, significantly lower than peers like Myriad Genetics and Amgen, while its stock performance has outpaced the Sensex, indicating potential market undervaluation.
As of 5 October 2023, Cidara Therapeutics, Inc. moved from fair to attractive. The company is currently undervalued. Key ratios include a price-to-earnings ratio of 15.2, a price-to-book ratio of 1.8, and a debt-to-equity ratio of 0.4. When compared to peers, Myriad Genetics, Inc. has a price-to-earnings ratio of 20.5, and Amgen Inc. shows a price-to-book ratio of 4.0, indicating that Cidara is trading at a discount relative to its industry counterparts.

Additionally, Cidara's recent stock performance has outpaced the Sensex, reinforcing the valuation story and suggesting that the market may not fully recognize its potential.
{{stockdata.stock.stock_name.value}} Live

{{stockdata.stock.price.value}} {{stockdata.stock.price_difference.value}} ({{stockdata.stock.price_percentage.value}}%)

{{stockdata.stock.date.value}} | BSE+NSE Vol: {{stockdata.index_name}} Vol: {{stockdata.stock.bse_nse_vol.value}} ({{stockdata.stock.bse_nse_vol_per.value}}%)


Our weekly and monthly stock recommendations are here
Loading...
{{!sm.blur ? sm.comp_name : ''}}
Industry
{{sm.old_ind_name }}
Market Cap
{{sm.mcapsizerank }}
Date of Entry
{{sm.date }}
Entry Price
Target Price
{{sm.target_price }} ({{sm.performance_target }}%)
Holding Duration
{{sm.target_duration }}
Last 1 Year Return
{{sm.performance_1y}}%
{{sm.comp_name}} price as on {{sm.todays_date}}
{{sm.price_as_on}} ({{sm.performance}}%)
Industry
{{sm.old_ind_name}}
Market Cap
{{sm.mcapsizerank}}
Date of Entry
{{sm.date}}
Entry Price
{{sm.opening_price}}
Last 1 Year Return
{{sm.performance_1y}}%
Related News